21 results on '"Wijatyk, Anna"'
Search Results
2. Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy: Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/ Refractory (R/R) DLBCL (DALY II USA NCT04792489)
3. An efficient method for the synthesis of 6,7-bis(alkylthio- or alkylamino-substituted)quinoline-5,8-diones via nucleophilic addition/oxidation of alkylthio and alkylamino derivatives to quinoline-5,8-dione
4. Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa
5. Abstract 1677: Characterization of the pharmacodynamic activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1 antibody balstilimab
6. 267 Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer
7. 377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects
8. 256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699)
9. AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies.
10. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation
11. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
12. Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study
13. Maribavir Versus Valganciclovir for Pre-Emptive Treatment of Cytomegalovirus Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients
14. Intrathecal delivery of recombinant human arylsulfatase A in children with late-infantile metachromatic leukodystrophy
15. Maribavir for Treatment of Cytomegalovirus (CMV) Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant (SCT) or Solid Organ Transplant (SOT) Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study
16. Maribavir Versus Valganciclovir for Preemptive Treatment of Cytomegalovirus (CMV) Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant (SCT) and Solid Organ Transplant (SOT) Recipients
17. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
18. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
19. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
20. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study
21. HGT-REP-059 treatment protocol: effect and tolerability of open-label agalsidase alfa in patients with Fabry disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.